Literature DB >> 17064685

Two types of GABAergic miniature inhibitory postsynaptic currents in mouse substantia gelatinosa neurons.

Ayako Takahashi1, Atsushi Tokunaga, Hiroki Yamanaka, Takashi Mashimo, Koichi Noguchi, Ichiro Uchida.   

Abstract

The physiological and pharmacological properties of gamma-aminobutyric acid (GABA)ergic miniature inhibitory postsynaptic currents (mIPSCs) were investigated in substantia gelatinosa neurons of mouse spinal cord using whole-cell patch clamp recordings. Two cell populations were pharmacologically identified based on the effect of propofol (10 muM) on the mIPSC decay kinetics: those exhibiting propofol-sensitive mIPSCs, with a slow decay kinetic (mIPSC(SLOW)), and those exhibiting propofol-resistant mIPSCs, with a fast decay kinetic (mIPSC(FAST)) (decay time constants of 14.2+/-0.7 and 7.4+/-0.8 ms, respectively). The frequency and amplitude of both types of mIPSCs were not affected by propofol. Miniature IPSC(FAST) showed midazolam insensitivity, while midazolam prolonged the decay phase of mIPSC(SLOW) without modulation of the frequency and amplitude. Exogenous GABA-evoked responses in the neurons with mIPSC(SLOW) were potentiated by propofol, while those in neurons with mIPSC(FAST) were unaffected by propofol. Furthermore, non-stationary noise analysis of the two kinetically and pharmacologically distinct mIPSCs revealed different conductance of GABA(A) receptor channels underlying the synaptic events. Pharmacological responses to propofol and midazolam suggested that mIPSC(FAST) and mIPSC(SLOW) in substantia gelatinosa neurons can be mediated by GABA(A) receptors with different subunit compositions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064685     DOI: 10.1016/j.ejphar.2006.09.047

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Pre- and postsynaptic modulation of monosynaptic reflex by GABAA receptors on turtle spinal cord.

Authors:  Wendy Bautista; Justo Aguilar; José Emanuel Loeza-Alcocer; Rodolfo Delgado-Lezama
Journal:  J Physiol       Date:  2010-06-02       Impact factor: 5.182

2.  Expression of GABA(A) receptor alpha3-, theta-, and epsilon-subunit mRNAs during rat CNS development and immunolocalization of the epsilon subunit in developing postnatal spinal cord.

Authors:  J-R Pape; S S Bertrand; P Lafon; M-F Odessa; M Chaigniau; J K Stiles; M Garret
Journal:  Neuroscience       Date:  2009-02-26       Impact factor: 3.590

Review 3.  Chloride regulation in the pain pathway.

Authors:  Theodore J Price; Fernando Cervero; Michael S Gold; Donna L Hammond; Steven A Prescott
Journal:  Brain Res Rev       Date:  2008-12-31

4.  A validated cellular biobank for β-thalassemia.

Authors:  Lucia Carmela Cosenza; Laura Breda; Giulia Breveglieri; Cristina Zuccato; Alessia Finotti; Ilaria Lampronti; Monica Borgatti; Francesco Chiavilli; Maria Rita Gamberini; Stefania Satta; Laura Manunza; Franca Rosa De Martis; Paolo Moi; Stefano Rivella; Roberto Gambari; Nicoletta Bianchi
Journal:  J Transl Med       Date:  2016-09-02       Impact factor: 5.531

Review 5.  The Effects of General Anesthetics on Synaptic Transmission.

Authors:  Xuechao Hao; Mengchan Ou; Donghang Zhang; Wenling Zhao; Yaoxin Yang; Jin Liu; Hui Yang; Tao Zhu; Yu Li; Cheng Zhou
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

6.  The α5 subunit containing GABAA receptors contribute to chronic pain.

Authors:  Mariana Bravo-Hernández; José A Corleto; Paulino Barragán-Iglesias; Ricardo González-Ramírez; Jorge B Pineda-Farias; Ricardo Felix; Nigel A Calcutt; Rodolfo Delgado-Lezama; Martin Marsala; Vinicio Granados-Soto
Journal:  Pain       Date:  2016-03       Impact factor: 7.926

7.  Steady-state activation and modulation of the synaptic-type α1β2γ2L GABAA receptor by combinations of physiological and clinical ligands.

Authors:  Allison L Germann; Spencer R Pierce; Thomas C Senneff; Ariel B Burbridge; Joe Henry Steinbach; Gustav Akk
Journal:  Physiol Rep       Date:  2019-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.